ArticleCrohn's & colitis 3602021

Favorable Outcomes Combining Vedolizumab With Other Biologics or Tofacitinib for Treatment of Inflammatory Bowel Disease.

Ernesto M Llano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.